3705-27-9O=C1NCC(=O)N2CCC[C@@H]12OWOHLURDBZHNGG-YFKPBYRVSA-NNA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy with Atazanavir and Dexamethasone for COVID-19).
3705-27-9、97011-16-0DTXSID601384588CHEMBL360216Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
UsesCyclo(-Gly-Pro) and its derivatives can be used as Cyclic Dipeptide Chitinase Inhibitors. It is also used to synthesize 5-HT1A receptor agonists.
Loading…